everolimus + sirolimus

Everolimus and sirolimus are both small molecule inhibitors of the mammalian target of rapamycin (mTOR), used primarily as immunosuppressants to prevent organ transplant rejection and as antineoplastic agents in various cancers. Everolimus is a derivative of sirolimus, differing by an additional hydroxyethyl group, which results in distinct pharmacokinetic properties such as higher bioavailability and a shorter half-life compared to sirolimus. Both drugs act by binding to FKBP12, forming a complex that inhibits mTORC1 activity, leading to cell cycle arrest at the G1 phase, reduced cell proliferation, angiogenesis inhibition, and immunosuppression through blockade of T-cell and B-cell activation. Everolimus is also approved for use in certain types of advanced cancers including breast cancer, renal cell carcinoma, neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex (TSC), and partial-onset seizures with TSC. Sirolimus is widely used for kidney transplant rejection prophylaxis and has applications in drug-eluting stents due to its antiproliferative effects[1][2][3][4][5][6].

Other names

RAD001 (everolimus)rapamycin (sirolimus)